stoxline Quote Chart Rank Option Currency Glossary
Adagene Inc. (ADAG)
2.885  -0.025 (-0.86%)    06-12 16:00
Open: 2.84
High: 2.9587
Volume: 6,548
Pre. Close: 2.91
Low: 2.82
Market Cap: 127(M)
Technical analysis
2024-06-12 4:20:09 PM
Short term     
Mid term     
Targets 6-month :  3.62 1-year :  4.22
Resists First :  3.09 Second :  3.62
Pivot price 2.75
Supports First :  2.42 Second :  2
MAs MA(5) :  2.92 MA(20) :  2.71
MA(100) :  2.9 MA(250) :  2.09
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  73.2 D(3) :  76.7
RSI RSI(14): 57.4
52-week High :  4.38 Low :  1.1
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ADAG ] has closed below upper band by 27.7%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.96 - 2.98 2.98 - 2.99
Low: 2.78 - 2.8 2.8 - 2.81
Close: 2.85 - 2.88 2.88 - 2.91
Company Description

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Headline News

Thu, 13 Jun 2024
Adagene Inc. (NASDAQ:ADAG) Sees Large Drop in Short Interest - Defense World

Thu, 30 May 2024
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 26.5% - MarketBeat

Wed, 29 May 2024
Comparing Adagene (NASDAQ:ADAG) and Galera Therapeutics (NASDAQ:GRTX) - Defense World

Fri, 29 Mar 2024
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewswire

Thu, 07 Mar 2024
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - GlobeNewswire

Fri, 09 Feb 2024
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 44 (M)
Held by Insiders 1.271e+007 (%)
Held by Institutions 4.1 (%)
Shares Short 14 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.274e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -104.7 %
Operating Margin -2 %
Return on Assets (ttm) 288.8 %
Return on Equity (ttm) -11.1 %
Qtrly Rev. Growth 1.811e+007 %
Gross Profit (p.s.) -136.78
Sales Per Share -39.78
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -28 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.08
Price to Cash Flow 1.11
Stock Dividends
Dividend 0
Forward Dividend 11100
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android